A USD 1.6 million Small Business Innovation Research Phase II grant was awarded to biopharmaceutical company Signum Dermalogix from the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Signum Dermalogix
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Social Security Benefits: 2025 COLA Predicted to Increase Amid Rising Inflation
- 940,000 Taxpayers May Receive Extra $932 Tax Refunds From IRS; Here's Why!
- American Airlines Pilots Union Issues Urgent Safety Alert Over Maintenance Issues
- Innocent Female Uber Driver, 61, Shot Dead by 81-Year-Old Ohio Man Who Was Targeted by Scammers
- Google Starts Removing Links to California News Websites in Response to Journalism Preservation Act
- Customers Rush into 99 Cents Only Stores in California Ahead of Closures
- Spirit Airlines Staff at Florida Airport Filmed Cursing a 'Karen' Passenger After Moaning About Her Flight
- Donald Trump Urges His Followers to Support Truth Social as Its Parent Company’s Stock Continues to Dive
